European Commission logo
English English
CORDIS - EU research results

AI-powered pathological cancer diagnostics

Project description

Artificial intelligence in cancer diagnosis

As the number of cancer cases worldwide increases, there is a pressing need for prompt and accurate cancer diagnosis. Existing approaches are time-consuming and depend heavily on the knowledge and experience of trained pathologists. To overcome these limitations, the EU-funded AIPACA project aims to develop an artificial intelligence-based software capable of analysing biopsy slides within seconds to identify tumour regions and quantify tumour biomarkers. The software is expected to significantly reduce biopsy processing time and assist diagnosis through deep learning features. Moreover, it will minimise variations in diagnosis, offering a robust and reliable clinical tool.


MindPeak is an innovative start-up that builds diagnostic support tools for cancer diagnosis. Our Artificial Intelligence (AI) software analyses biopsy slides within seconds to find tumour regions and quantify tumour markers to prepare them for visual inspection by the pathologist. In 2018, the number of diagnosed cancer cases has grown to 18 million globally.
Consequently, the demand for cancer diagnosis to determine appropriate treatment has never been higher. Cancer diagnosis nowadays is a very time-consuming process and depends heavily on the knowledge and experience of specialised pathologists. Unfortunately, the number of experts can no longer meet the quickly increasing demand. As a result, patients must wait longer than necessary for their diagnosis.
To overcome this challenge, MindPeak provides solutions based on deep learning to support pathologists in their diagnosis. Patients benefit from increased accuracy and a faster turn around time of diagnosis as well as reduced costs. The key USP of our AI is its reliability in the clinical context with its variations across and within labs. Funding from the EIC Accelerator will help us with a successful and fast go-to-market of our solutions that cover crucial improvements for cancer patients. With our technology, we address the market for pathology with a current size of $17.3 bn worldwide and an annual growth rate of 6.5%.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 1 372 378,00
20359 Hamburg

See on map


The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Hamburg Hamburg Hamburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Total cost
€ 1 960 540,00